Cardiovascular properties of the kallikrein-kinin system.
All the components of the kallikrein-kinin system are located in the vascular smooth muscle as well as in the heart. In recent years, numerous observations obtained from clinical and experimental models of diabetes, hypertension, cardiac failure, ischaemia, myocardial infarction and left ventricular hypertrophy, have suggested that the reduced activity of the local kallikrein-kinin system may be instrumental in the induction of cardiovascular-related diseases. The ability of kallikrein gene delivery to produce a wide spectrum of beneficial effects makes it an excellent candidate in treating hypertension, and cardiovascular and renal diseases. In addition, stable kinin agonists may also be available in the future as therapeutic agents for cardiovascular and renal disorders.
Sharma
Jagdish N
JN
Department of Applied Therapeutics, Faculty of Pharmacy, Kuwait University, Safat. j.n.sharma@hsc.kuniv.edu.kw
Sharma
Jyoti
J
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D001794:Blood Pressure / Q000502:physiology; D065168:Bradykinin Receptor Antagonists; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000503:physiopathology*; D019446:Endotoxemia / Q000209:etiology / Q000503:physiopathology; D006333:Heart Failure / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000209:etiology; D017379:Hypertrophy, Left Ventricular / Q000209:etiology / Q000503:physiopathology; D016234:Kallikrein-Kinin System / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D007705:Kinins / Q000187:drug effects / Q000502:physiology*; D051381:Rats; D018002:Receptors, Bradykinin / Q000502:physiology*
D000806:Angiotensin-Converting Enzyme Inhibitors; D065168:Bradykinin Receptor Antagonists; D007705:Kinins; D018002:Receptors, Bradykinin